Curis, Inc.
As of Oct 22, 2026, Curis is in Stage 4, the downtrend phase, now in week 63 (since Jul 29, 2025). It closed at $0.40, 98.8% below its 52-week high and below its 200-day average, which is falling.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CRIS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CRIS among Biotechnology542nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …542 | CRIS | Stage 4 · wk 63 | 3 | −57.9% |
Curis: quick answers
What stage is Curis in?
As of Oct 22, 2026, Curis (CRIS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 29, 2025 and is in week 63. What the four stages mean
Is Curis in an uptrend?
No. Curis is in a Stage 4 downtrend. It trades 95.8% below its 200-day average, which is falling.
How far is Curis from its 52-week high?
Curis closed at $0.40 on Oct 22, 2026, 98.8% below its 52-week high of $32.60. Its 52-week low is $0.38.
How has Curis performed over the past year?
As of Oct 22, 2026, Curis is down 98.7% over the past year and down 98.0% so far in 2026.
Which sector and industry is Curis in?
Curis is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.